{"id":2959,"date":"2021-06-23T18:18:38","date_gmt":"2021-06-23T21:18:38","guid":{"rendered":"https:\/\/www.atlanticpath.ca\/?p=2959"},"modified":"2021-06-27T18:21:00","modified_gmt":"2021-06-27T21:21:00","slug":"early-results-from-canpaths-national-study-confirm-antibody-levels-are-stronger-after-receiving-two-doses-of-covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/www.atlanticpath.ca\/index.php\/2021\/06\/23\/early-results-from-canpaths-national-study-confirm-antibody-levels-are-stronger-after-receiving-two-doses-of-covid-19-vaccine\/","title":{"rendered":"Early results from CanPath\u2019s national study confirm antibody levels are stronger after receiving two doses of COVID-19 vaccine"},"content":{"rendered":"<p>Initial preliminary results from the\u00a0<a href=\"https:\/\/canpath.ca\/\">Canadian Partnership for Tomorrow\u2019s Health<\/a>\u00a0(CanPath) COVID-19 Antibody Study, based on close to 6,000 dried blood spot samples collected between February 8 and May 17, 2021, show a high degree of variability in the level of antibodies produced by a single dose of a COVID-19 vaccine. These findings highlight the importance of accelerating second doses as the Delta variant continues to spread, particularly with the vast majority of Canadians having received only a single vaccine dose. This is the first pan-Canadian study using samples from a wide range of participants to confirm evidence from vaccine manufacturers\u2019 clinical trials, as well as findings in a\u00a0<a href=\"https:\/\/www.medrxiv.org\/content\/10.1101\/2021.04.22.21255911v1\">recent preprint<\/a>\u00a0from the United Kingdom and other smaller studies.<\/p>\n<p>&nbsp;<\/p>\n<p>Participants from Atlantic PATH, CARTaGENE, the Ontario Health Study, Manitoba Tomorrow Project, Alberta\u2019s Tomorrow Project, and BC Generations contributed to the COVID-19 Antibody Study.<\/p>\n<p><a href=\"https:\/\/bit.ly\/3gVLeb2\">https:\/\/bit.ly\/3gVLeb2<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Initial preliminary results from the\u00a0Canadian Partnership for Tomorrow\u2019s Health\u00a0(CanPath) COVID-19 Antibody Study, based on close to 6,000 dried blood spot samples collected between February 8 and May 17, 2021, show a high degree of variability in the level of antibodies produced by a single dose of a COVID-19 vaccine. These findings highlight the importance of accelerating second doses as the Delta variant continues to spread, particularly with the vast majority of Canadians having received only a single vaccine dose. This is the first pan-Canadian study using samples from a wide range of participants to confirm evidence from vaccine manufacturers\u2019 clinical trials, as well as findings in a\u00a0recent preprint\u00a0from the United Kingdom and other smaller studies. &nbsp; Participants from Atlantic PATH, CARTaGENE, the Ontario Health Study, Manitoba Tomorrow Project, Alberta\u2019s Tomorrow Project, and BC Generations contributed to the COVID-19 Antibody Study. https:\/\/bit.ly\/3gVLeb2 &nbsp;<\/p>\n","protected":false},"author":1,"featured_media":2961,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_eb_attr":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":"","_wpscppro_dont_share_socialmedia":false,"_wpscppro_custom_social_share_image":0,"_facebook_share_type":"","_twitter_share_type":"","_linkedin_share_type":"","_pinterest_share_type":"","_linkedin_share_type_page":"","_instagram_share_type":"","_medium_share_type":"","_threads_share_type":"","_selected_social_profile":[],"_wpsp_enable_custom_social_template":false,"_wpsp_social_scheduling":{"enabled":false,"datetime":null,"platforms":[],"status":"template_only","dateOption":"today","timeOption":"now","customDays":"","customHours":"","customDate":"","customTime":"","schedulingType":"absolute"},"_wpsp_active_default_template":true},"categories":[3],"tags":[],"class_list":["post-2959","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"modified_by":"pathwp","_links":{"self":[{"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/posts\/2959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/comments?post=2959"}],"version-history":[{"count":1,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/posts\/2959\/revisions"}],"predecessor-version":[{"id":2962,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/posts\/2959\/revisions\/2962"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/media\/2961"}],"wp:attachment":[{"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/media?parent=2959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/categories?post=2959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/tags?post=2959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}